Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
Carcinoma, Renal Cell
Matrix Metalloproteinase 2
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-3
Von Hippel-Lindau Tumor Suppressor Protein
Serum Ang-2 and MMP-2 and tumor HIF-1α were identified as relevant baseline biomarkers of sunitinib activity in advanced RCC, warranting further research into their prognostic versus predictive value.